Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Detalles Bibliográficos
Autores principales: Restelli, Umberto, Fabbiani, Massimiliano, Di Giambenedetto, Simona, Nappi, Carmela, Croce, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627749/
https://www.ncbi.nlm.nih.gov/pubmed/29026324
http://dx.doi.org/10.2147/CEOR.S143377
_version_ 1783268762378567680
author Restelli, Umberto
Fabbiani, Massimiliano
Di Giambenedetto, Simona
Nappi, Carmela
Croce, Davide
author_facet Restelli, Umberto
Fabbiani, Massimiliano
Di Giambenedetto, Simona
Nappi, Carmela
Croce, Davide
author_sort Restelli, Umberto
collection PubMed
description
format Online
Article
Text
id pubmed-5627749
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56277492017-10-12 Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial Restelli, Umberto Fabbiani, Massimiliano Di Giambenedetto, Simona Nappi, Carmela Croce, Davide Clinicoecon Outcomes Res Original Research Dove Medical Press 2017-09-27 /pmc/articles/PMC5627749/ /pubmed/29026324 http://dx.doi.org/10.2147/CEOR.S143377 Text en © 2017 Restelli et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Restelli, Umberto
Fabbiani, Massimiliano
Di Giambenedetto, Simona
Nappi, Carmela
Croce, Davide
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
title Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
title_full Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
title_fullStr Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
title_full_unstemmed Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
title_short Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
title_sort update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of hiv-positive patients receiving atazanavir-based triple therapies in italy starting from data of the atlas-m trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627749/
https://www.ncbi.nlm.nih.gov/pubmed/29026324
http://dx.doi.org/10.2147/CEOR.S143377
work_keys_str_mv AT restelliumberto updateofthebudgetimpactanalysisofthesimplificationtoatazanavirritonavirlamivudinedualtherapyofhivpositivepatientsreceivingatazanavirbasedtripletherapiesinitalystartingfromdataoftheatlasmtrial
AT fabbianimassimiliano updateofthebudgetimpactanalysisofthesimplificationtoatazanavirritonavirlamivudinedualtherapyofhivpositivepatientsreceivingatazanavirbasedtripletherapiesinitalystartingfromdataoftheatlasmtrial
AT digiambenedettosimona updateofthebudgetimpactanalysisofthesimplificationtoatazanavirritonavirlamivudinedualtherapyofhivpositivepatientsreceivingatazanavirbasedtripletherapiesinitalystartingfromdataoftheatlasmtrial
AT nappicarmela updateofthebudgetimpactanalysisofthesimplificationtoatazanavirritonavirlamivudinedualtherapyofhivpositivepatientsreceivingatazanavirbasedtripletherapiesinitalystartingfromdataoftheatlasmtrial
AT crocedavide updateofthebudgetimpactanalysisofthesimplificationtoatazanavirritonavirlamivudinedualtherapyofhivpositivepatientsreceivingatazanavirbasedtripletherapiesinitalystartingfromdataoftheatlasmtrial

Ejemplares similares